Published in Eur Psychiatry on June 25, 2009
Toward meeting the needs of homeless people with schizophrenia: the validity of quality of life measurement. PLoS One (2013) 0.82
Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci (2014) 0.80
Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia. Qual Life Res (2012) 0.80
Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry (2015) 0.76
Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome. Neuropsychiatr Dis Treat (2015) 0.75
A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients. J Clin Psychopharmacol (2017) 0.75
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res (2001) 4.08
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry (2008) 3.85
LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia. Mol Psychiatry (2007) 3.49
Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology (1998) 3.44
Mind reading: neural mechanisms of theory of mind and self-perspective. Neuroimage (2001) 3.03
Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol (1991) 3.03
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatr Scand (2004) 2.84
The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J (1993) 2.74
Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol (1997) 2.70
Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care (1997) 2.63
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates. Gene (1984) 2.44
Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care (1997) 2.32
Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry (2009) 2.29
WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry (1994) 2.25
Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest (1982) 2.23
The Hamilton scales and the Hopkins Symptom Checklist (SCL-90). A cross-national validity study in patients with panic disorders. Br J Psychiatry (1992) 2.16
Net costs of dementia by disease stage. Acta Psychiatr Scand (2011) 2.11
Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry (2008) 2.07
Low lumbar bone mineral density in patients with major depression. Am J Psychiatry (1994) 2.05
Geographical prevalence of two types of Epstein-Barr virus. Virology (1986) 2.05
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet (1999) 1.98
Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res (1998) 1.95
Quantification of secondary dentine formation from orthopantomograms--a contribution to forensic age estimation methods in adults. Int J Legal Med (2004) 1.95
Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm (Vienna) (2005) 1.85
Subcortical correlates of craving in recently abstinent alcoholic patients. Am J Psychiatry (2001) 1.84
Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J (2005) 1.83
Two distant clusters of partially homologous small repeats of Epstein-Barr virus are transcribed upon induction of an abortive or lytic cycle of the virus. J Virol (1983) 1.82
The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol (1999) 1.81
Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med (1992) 1.80
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology (2012) 1.78
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
Risk factors for incident mild cognitive impairment--results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Acta Psychiatr Scand (2009) 1.76
The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord (1988) 1.74
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand (2010) 1.67
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand (2005) 1.67
Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis. Mol Psychiatry (1997) 1.66
Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol Psychiatry (2011) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry (2004) 1.63
Target sequences for cis-acting regulation within the dual promoter of the human c-myc gene. Mol Cell Biol (1987) 1.63
Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain (2006) 1.62
A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann Neurol (2000) 1.61
SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry (2004) 1.60
Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry (2004) 1.60
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand (2008) 1.59
Evaluation of linkage of bipolar affective disorder to chromosome 18 in a sample of 57 German families. Mol Psychiatry (1999) 1.59
Structure and evolution of two related transcription units of Epstein-Barr virus carrying small tandem repeats. J Virol (1985) 1.59
New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J Gen Virol (1987) 1.58
Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. Br J Psychiatry Suppl (1998) 1.57
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol (1996) 1.57
Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies. Eur Arch Psychiatry Clin Neurosci (2002) 1.56
Regional differences in the prevalence of known Type 2 diabetes mellitus in 45-74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabet Med (2012) 1.56
Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting. Implications for mechanical plaque sealing. Eur Heart J (2003) 1.55
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2008) 1.54
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol (1998) 1.51
A congenital teratoma with a cleft palate: report of a case. Br J Oral Maxillofac Surg (2005) 1.50
Moderate alcohol consumption in social drinkers raises plasma homocysteine levels: a contradiction to the 'French Paradox'? Alcohol Alcohol (2001) 1.50
Lyme disease presenting as Tourette's syndrome. Lancet (1998) 1.50
Parentification and its impact on adolescent children of parents with AIDS. Fam Process (1999) 1.50
Essential functions of the human self model are implemented in the prefrontal cortex. Conscious Cogn (1999) 1.48
Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine. Pharmacopsychiatry (1996) 1.48
[Care requirements for severe mental disorders. Scientific evidence for integration of clinical psychiatry and community psychiatry]. Nervenarzt (2005) 1.46
Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry (2004) 1.46
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med (2011) 1.45
CADASIL: underdiagnosed in psychiatric patients? Acta Psychiatr Scand (2005) 1.45
A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. Mol Psychiatry (2000) 1.45
Risk factors for new depressive episodes in primary health care: an international prospective 12-month follow-up study. Psychol Med (2002) 1.44
Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology (2000) 1.44
Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab (1997) 1.44
The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease. Acta Psychiatr Scand (2011) 1.43
Slippery surfaces of pitcher plants: Nepenthes wax crystals minimize insect attachment via microscopic surface roughness. J Exp Biol (2010) 1.43
[Personality, accentuated traits and personality disorders. A contribution to dimensional diagnosis of personality disorders]. Nervenarzt (2002) 1.43
Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res (1993) 1.43
Genome-wide survey implicates the influence of copy number variants (CNVs) in the development of early-onset bipolar disorder. Mol Psychiatry (2011) 1.43
A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. Hum Mol Genet (2001) 1.42
[From "schizophrenia" to "disturbance of the integrity of the self": causes and consequences of renaming schizophrenia in Japan in 2002]. Nervenarzt (2011) 1.41
Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry (2010) 1.41
Regional heterogeneity of cerebral blood flow response to graded volume-controlled hemorrhage. Intensive Care Med (1996) 1.40
Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry (2011) 1.40
[Chondrosarcoma of the larynx. Experience gained in Freiburg since 1999]. HNO (2011) 1.40
[Core symptoms of depression. Effectiveness of antidepressant therapy]. Nervenarzt (2009) 1.40
Subclinical hypothyroidism in recurrent mania. Biol Psychiatry (1992) 1.40
T-cell subsets and expression of integrins in peripheral blood of patients with migraine. Cephalalgia (1999) 1.40
Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry (2003) 1.40
[Infant mortality, age of the mothers and number of children]. Arch Gynakol (1965) 1.39
[Guidelines based on decision support software. Quality management in neurological outpatient schizophrenia treatment]. Nervenarzt (2006) 1.39
Prolonged confusional state following electroconvulsive therapy--diagnostic clues from serial electroencephalography. Pharmacopsychiatry (2005) 1.39
[Encephalopathy following poisoning with an anticholinergic agent]. Dtsch Med Wochenschr (1994) 1.39